John Christensen

Emeritus Faculty
jmark.christensen@oregonstate.edu

Office: 541-737-5788

Pharmacy Building

Pharmacy Building 229

1601 SW Jefferson Avenue

1601 SW Jefferson Avenue
Corvallis, OR 97331
Credentials: 
University of Utah, Ph.D., 1980; B.S., 1975 (RPh).

Profile Field Tabs

At OSU
Affiliated with: 
Pharmacy Professnl Instr
Headquarters: 
OSU Main Campus
Faculty Type: 
Emeritus
Research/Career Interests: 

J. Mark Christensen's research takes three basic thrusts within the areas of biopharmaceutics, pharmacokinetics and drug dosage formulation. In response to the growing importance of drug therapy in animals, one research area, done in collaboration with faculty from the College of Veterinary Medicine, looks at drug disposition in animals. In another area, similar research techniques are applied to determining drug dosing and disposition in humans, how drugs are absorbed, eliminated and metabolized. The development of sustained action oral dosage forms with respect to their performance, production, and in-vivo characteristics provide the last area of research.

Selected Publications

Loan Pham, J. Mark Christensen. “Preparation of Acetaminophen capsules containing beads prepared by Hot-Melt Direct Blend Coating.” Accepted for Publication November 30, 2012 Pharmaceutical Development and Technology.

Loan Pham, John Mark Christensen, Rosita Rodriguez-Proteau. “Pharmacokinetic Prediction of Levofloxacin Accumulation in Tissue and its Association to Tendinopathy.” Accepted for Publication November 21, 2012, Pharmacology and Pharmacy.

Dove J Keith, J A Butler, B Bemer, B Dixon, S Johnson, M Garrard, D L Sudakin, John Mark Christensen, C Pereira, and T M Hagen. “Age and gender dependent bioavailability of R- and R, S-α-lipoic acid: a Pilot Study.”  Pharmacological Research, 2012 66(3): 199-206. 

LeeCole Legette, Lian Ma, Ralph L. Reed, Christobal L. Miranda, J Mark Christensen, Rosita Rodriguez-Proteau, and Jan F. Stevens. “Pharmacokinetics of Xanthohumol and Metabolites After Oral and Intravenous Administration.” Molecular Nutrition and Food Research. 2012 March (3) 56:466-74. DOI: 10.1002/mnfr.20110554.

Sahar Fahmy, John Mark Christensen, and Lian Ma. “In vitro and In vivo Evaluation of Pesticidal and Ovicidal Activities of Chemical Pesticides of OTC Products, Home Remedies, Essential Oils, and Other Factors Associated with Efficacy of Treatment of Head Lice Infestations.” Journal of Pharmaceutical Research and Clinical Practice. 2012, 2(1): 1-13.

Chien Nguyen, J. Mark Christensen and James W. Ayres. “Novel Sustained Release Tablet of Glipizide: Compression of Coated Drug Beads, Formulation and Dissolution.” Accepted for Publication 11/2/2012, Pharmaceutical Development and Technology.

Clive Kaiser, Philip B. Hamm, Stacy Gieck, Nicolas DavidJ. Mark Christensen. “In Vitro Fungicidal, and Bactericidal Activity of Calcium and Potassium Salts of Several Commercially Significant Fungi and Bacteria in the Pacific Northwest.”  HortScience 46(6):913-916.

John Mark Christensen, Monica Chuong, Hang Le, Ehab Bendas, and Loan Pham. “Hydrocortisone Diffusion Through Synthetic Membrane, Mouse Skin, And EpiDermTM Cultured Skin.” Archives of Drug Information (2011) 4(1): 10-21. 

Norman D. Forsberg, Rosita Rodriguez-Proteau, Lian Ma, Jeffrey Morre, J. Mark Christensen, Claudia S Maier, Jeffrey J Jenkins, Kim A Anderson. “Organophosphorus Pesticide Degradation Product In Vitro Metabolic Stability and Time-Course Uptake and Elimination in Rats Following Oral and Intravenous Dosing.” Xenobiotica (2011) 41(5):422-429.

Chien Nguyen, J. Mark Christensen and James W. Ayres. “Verapamil Sustained Release: New Formulation and Convolution.”   Pharmaceutical Development and Technology. (March 2012) 17 (2): 148-57.

Chien Nguyen, J. Mark Christensen, and James W. Ayres.” Novel Mesalamine Loaded Beads for Delayed Release of Drug to the Colon.”   Pharmaceutical Development and Technology (February 2012), 17 (1): 73–83. 

Ursula Bechert, J. Mark Christensen, Robert Poppenga, Sahar A. Fahmy and Patrick Redig. “Pharmacokinetics of Terbinafine after Single Oral Dose Administration in Red-tailed Hawks (Buteo Jamaicensis)”. Journal of Avian Medicine and Surgery (2010) 24(2):122-130. 

Ursula Bechert, J. Mark Christensen, Robert Poppenga, Hang Le, Jeff Wyatt and Todd Schmitt. “Single Oral and Multiple Dose Pharmacokinetics of Terbinafine in African Penguins (Sphenicus Demersus)”. Journal of Zoo and Wildlife Medicine (2010) 41(2):263-274.

Ehab R. Bendas, J. Mark Christensen, James W. Ayres. “Development and In-vitro Evaluation of Mesalamine Delayed-Release Pellets and Tableted Reservoir-Type Pellets”. Accepted for Publication August 27,2009. Drug Development and Industrial Pharmacy. 

Sahar A. Fahmy, J. Mark Christensen, James W. Ayres, “Development of a Novel Spay Coated Soft Elastic Gelatin Capsule Sustained Release Formulations of Nifedipine.”  Drug Development and Industrial Pharmacy. August (2009), Volume 35(8):1009-1021. 

Monica C. Chuong, J. Mark Christensen, and James W. Ayres, “Sustained Delivery of Intact drug to the Colon: Mesalamine Formulation and temporal Gastrointestinal Transit Analysis,” Pharmaceutical Technology and Development, February (2009), Volume 14 (no. 1):116-125.

Monica C. Chuong, J. Mark Christensen, James W. Ayres, “New Dissolution Method for Mesalamine Tablets and Capsules,” Dissolution Technologies. (2008, August), Volume 15, issue 3:7-14. 

David Bearden, George Allen, J. Mark Christensen, “Comparative in Vitro Activities of Topical Wound Care Products Against Community-Associated Methicillin-Resistant Staphylococcus Aureus”, Journal of Antimicrobial Chemotherapy, (2008), Volume 62:769-772. 

Ursula Bechert, J. Mark Christensen, Chien Nguyen, Roopesh Neelkant, and Ehab Bendas, “Pharmacokinetics of Orally Administered Phenylbutazone in African and Asian Elephants (Loxodonta Africana and Elephas Maximus)”, Journal of Zoo and Wildlife Medicine, (2008) 39(2):188-200. 

Chien N. Nguyen, J. Mark Christensen, James W. Ayres, Formulation of Sustained Release Verapamil HCl and Diltiazem HCl Solid Matrix Capsules, Pharmaceutical Development and Technology, (2008) 13(2):115-125.   

Grant Beardsley, and John Mark Christensen, Elimination of 11-nor-9-Carboxy-delta-9-Tetrahydrocannabinol when Normalized to Urinary Creatinine, Research Communications in Molecular Pathology and Pharmacology, (2007-2008) 120-121 (1-6):67-78. 

Prapoch Watanalumerd, J. Mark Christensen, and James W. Ayres, “Pharmacokinetic Modeling and Simulation of Gastrointestinal Transit Effects of Plasma Concentration of Drug from Mixed Immediate-Release and Enteric-Coated Pellets” Pharmaceutical Development and Technology (2007) 12(2): 193-202.

Ursula Bechert, J. Mark Christensen, “Pharmacokinetics of Orally Administered Ibuprofen in African and Asian Elephants (Loxodonta Africana and Elephas Maximus). Journal of Zoo and Wildlife Medicine (2007) 38 (2):258-268.  

Ursula Bechert, Patrick Redig, Jeff Wyatt, Robert Poppenga and Mark Christensen. “Pharmacokinetics and Clinical Efficacy of Terbinafine Against Aspergillosis in Avian Species”. Proceedings of American Association of Zoo Veterinarians.  (2004) Pages 241-244.

Ursula Bechert, J. Mark Christensen, and M. Finegan. “Pharmacokinetics of Orally Administered Ibuprofen in Elephants”. Proceedings of American Association of Zoo Veterinarians.  (2003) pages 84-85.

Christensen JM, Limsakum T, Smith BB, Holinghead N, Huber M. Pharmacokinetics of Antipeptic Agents in Llamas. Journal of Veterinary Pharmacology and Therapeutics. 2001;24:23-33. 

Smith BB, Timm KI, Reed PJ, Christensen JM. Use of Cloprostenol as an Abortifacient in the Llama (lama gama). Theriogenology. 2000;54:497-505.

Kalns J, and Christensen JM. Thrombomodulin like activity following intravenous injection of non-ionic surfactants in rats. Research Communications in Pharmacology and Toxicology. 2000;5:3-10.

Patents

United Kingdom: Number 2308300, Renebacterium Salmoninarum Vaccine and Method of It's Preparation. Notice of Award September 2, 1998. Inventors: J.M. Christensen, S. Kaattari, J. Piganelli, G. Wiens, A.J. Zhang.  United States: Number 5871751, Renebacterium Salmoninarum Vaccine and Method of Its Preparation. Notice of Award February 16, 1999. Inventors: J.M. Christensen, S. Kaattari, J. Piganelli, G. Wiens, A.J. Zhang.   Canada: Number 2,202,499. Notice of Award April 26, 1996.

Functional Group: